Applied UV Declares Monthly Preferred Stock Dividend

Applied UV Declares Monthly Preferred Stock Dividend
CANNANNEW REPORT

MOUNT VERNON, NY–(BUSINESS WIRE)–Applied UV, Inc. (NasdaqCM: AUVI) (“Applied UV” or the “Company”), a pathogen elimination technology company that applies the power of narrow-range ultraviolet light (“UVC”) for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically, today announced its Board of Directors has authorized the cash dividend to holders of Applied UV’s 10.5% Series A Cumulative Perpetual Preferred Stock. Holders of the 10.5% Series A Cumulative Perpetual Preferred Stock (Nasdaq: AUVIP) shall receive a cash dividend equal to $0.21875 per share. The return of capital will be paid on or about May 16, 2022, to respective holders of record at the close of business on May 4, 2022. About Applied UV Applied UV is focused on the development and acquisition of technology that address infection control in the healthcare, hospitality, commercial and municipal markets. The Company has two wholly owned subsidiaries – SteriLumen, Inc. (“SteriLumen”) and Munn Works, LLC (“Munn Works”). SteriLumen’s connected platform for Data Driven Disinfection™ applies the power of ultraviolet light (UVC) to destroy pathogens safely, thoroughly, and automatically, addressing the challenge of healthcare-acquired infections (“HAIs”). Targeted for use in facilities that have high customer turnover such as hospitals, hotels, commercial facilities, and other public spaces, the Company’s Lumicide™ platform uses UVC LEDs in several patented designs for infection control in and around high-traffic areas, including sinks and restrooms, killing bacteria, viruses, and other pathogens residing on hard surfaces within devices’ proximity. The Company’s patented in-drain disinfection device, Lumicide Drain, is the only product on the market that addresses this critical pathogen intensive location. SteriLumen’s Airocide® air purification devices are research backed, clinically proven and developed for NASA with assistance from the University of Wisconsin. Airocide® is listed as an FDA Class II Medical device, utilizes a proprietary photocatalytic…

Excerpt only …
READ MORE BELOW
Source : Applied UV Declares Monthly Preferred Stock Dividend

reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.